Sonoma Pharmaceuticals (NASDAQ:SNOA) Posts Earnings Results

Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its quarterly earnings results on Tuesday. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.09), FiscalAI reports. The company had revenue of $5.56 million during the quarter, compared to analyst estimates of $5.57 million. Sonoma Pharmaceuticals had a negative net margin of 16.26% and a negative return on equity of 43.95%.

Sonoma Pharmaceuticals Price Performance

SNOA opened at $1.15 on Friday. The stock’s 50 day moving average price is $1.37 and its two-hundred day moving average price is $2.46. Sonoma Pharmaceuticals has a 12-month low of $0.85 and a 12-month high of $6.92. The firm has a market capitalization of $5.51 million, a P/E ratio of -0.61 and a beta of 1.29.

Institutional Trading of Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. acquired a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned 0.66% of Sonoma Pharmaceuticals as of its most recent SEC filing. 1.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.